Maravai LifeSciences Holdings Inc. Class A (MRVI)
NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MRVI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.75B
- EPS (TTM)
- -$0.53
- Dividend yield
- None
- 52-week range
- 2.55 – 9.42
- Day range
- 7.22 – 7.73
- Volume / Avg
- 4.27M / 3.30M
- Beta
- —
- Shares outstanding
- 148.99M
- Next earnings
- Nov 5, 2026
52-week range
MRVI stock today
Shares of Maravai LifeSciences (MRVI) finished lower on Oct 7 at $7.43, a drop of 5.35% or $0.42 per share, versus the S&P 500's 0.22% decline. At this level, MRVI sits in the middle of its 52-week range of $2.55 to $9.42: 21.1% below the high, set on Aug 26, 2026 and 191.9% above the low. MRVI is up 128.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 124.5%.
Maravai LifeSciences has posted a net loss over the last twelve months (EPS of -$0.53), so its P/E ratio is not meaningful. Maravai LifeSciences's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Maravai LifeSciences
Company profileMaravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Bernd Brust
- Headquarters
- San Diego, CA
- Employees
- 415
- IPO year
- 2020
- Website
- maravai.com
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$7.83+5.38%
- Strong buy 0
- Buy 5
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.08
Maravai LifeSciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SDGRSchrodinger Inc. | 27.29 | -5.57% | $2.04B | vs MRVI |
| PRGOPerrigo Company plc | 14.55 | +3.93% | $2.01B | vs MRVI |
| VRDNViridian Therapeutics Inc. | 18.28 | +0.33% | $2.07B | vs MRVI |
| URGNUroGen Pharma Ltd. | 40.70 | -1.76% | $1.99B | vs MRVI |
| LKFTLakefront Biotherapeutics ADR | 30.00 | +2.32% | $1.96B | vs MRVI |
| MLYSMineralys Therapeutics Inc. | 22.09 | +0.64% | $1.95B | vs MRVI |
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs MRVI |
| ZYMEZymeworks Inc. | 26.53 | +3.43% | $1.90B | vs MRVI |
Indexes, lists and sector
Maravai LifeSciences stock FAQ
What is Maravai LifeSciences's stock price today?
MRVI last traded at $7.43 as of Oct 7, 4:00 PM EDT, down 5.35% on the day. Prices are delayed at least 15 minutes.
When is Maravai LifeSciences's next earnings date?
Maravai LifeSciences is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.08.
Who is Maravai LifeSciences's CEO?
Mr. Bernd Brust is the chief executive officer of Maravai LifeSciences Holdings Inc. Class A, which has about 415 employees.
What is the MRVI 52-week high?
The 52-week high for MRVI is $9.42 and the 52-week low is $2.55. The stock is currently 21.1% below its high.